Helix BioMedix Receives Key US Patent for its Bioactive Peptides
Helix BioMedix announced the issuance of U.S. Patent No. 6,875,744 entitled "Short Bioactive peptides." The patent covers a vast family of bioactive peptides designed for low cost synthesis and improved bioactivity. Specifically, this patent covers the composition of matter and use for peptides of five to 22 amino acids in length that consist, in large part, of four specific amino acids. This patent significantly expands the Company's technology platform of proprietary peptides for therapeutic and consumer product applications.
Peptides included in this patent form the basis of preclinical programs at Helix targeted at preventing wound infections and sexually transmitted diseases. In addition, this patent extends the Company's worldwide competitive edge in designing inexpensive peptides, a critical factor for the consumer goods market. In total, the Company now has nine issued patents in the U.S., nine issued foreign patents and four patents pending. Helix currently has research applications in such consumer markets as acne, skin care, wrinkle reduction, deodorants, and oral care. Based upon activities of peptides observed in nature, Helix has made advancements in all of these applications by exploiting the anti-infective and stimulatory properties of these short bioactive peptides.
Topics
Organizations
Other news from the department research and development
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.